With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU). Saint ...

Saint Herblain, France Tuesday, April 1, 2025, 16:00 Hrs [IST] ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory ...

The authorities on the French overseas territory of Réunion Island have issued a health alert after more than 4,000 new cases ...

Valneva responds to French govt’s call for supply of chikungunya vaccine, Ixchiq: Saint Herblain, France Wednesday, March 26, 2025, 17:00 Hrs [IST] Valneva SE, a specialty vacci ...

Valneva (NASDAQ:VALN – Get Free Report) had its target price dropped by research analysts at Guggenheim from $17.00 to $15.00 in a research note issued to investors on Monday,Benzinga reports. The ...

Thousands have been infected and two have been killed by the debilitating, mosquito-borne virus in the space of a few weeks ...

Valneva will work with local health authorities and wholesalers on the French island territory to distribute the vaccines.

Chikungunya cases have spiked substantially in La Réunion since early 2025, with 8,600 cases recorded and almost 3,000 new cases during the week of March 3 to 9, 2025 1. Similar to the 2005-2006 ...

LONDON, 24 Mar. 2025 (GLOBE NEWSWIRE) -- This is the Start of Day Message for GlobeNewswire. GlobeNewswire is operated by Notified and is designated by the FCA as an approved primary information ...

Valneva anticipates total product sales of €170 million to €180 million and total revenues of €180 million to €190 million for 2025, driven by increased IXCHIQ sales and growth in IXIARO and DUKORAL.

Prior to this approval, the only FDA approved vaccine for chikungunya prevention, Ixchiq (Valneva), was indicated for individuals aged 18 years and older. 1,2 “The commercial availability of VIMKUNYA™ ...